Answers are grounded in this paper and cite their sources.
Acquired aplastic anemia (AA) is a severe hematological disorder characterized primarily by bone marrow (BM) failure and hypoplastic myelopoiesis. Extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach for hematopoietic disorders. In the present study, MSCs‑derived EVs were isolated by differential ultracentrifugation after in vitro stimulation of MSCs with tetramethylpyrazine (TMP); EV identity was verified by nanoparticle tracking analysis, transmission electron microscopy and western blotting for surface markers. An AA mouse model was subsequently established via cyclophosphamide combined with busulfan conditioning to evaluate the therapeutic effects of EVs on BM hematopoiesis. Western blotting was used to detect the expression of signaling‑related proteins. Flow cytometry was performed to quantify T helper 17 (Th17) and regulatory T (Treg) cell proportions. The levels of hematopoietic cytokines were determined using an ELISA assay. And BM hematopoietic function was evaluated by blood cell counting and CD34 immunohistochemistry staining. TMP stimulation markedly increased EVs secretion into MSCs culture supernatants, potentially through the Rab27a/mammalian target of rapamycin complex 1 signaling axis. In vivo, EVs treatment significantly increased peripheral blood cell and BM nucleated cell counts, improved spleen indices and restored the disrupted Th17/Treg immune balance in AA mice. Moreover, EVs treatment effectively upregulated the expression of key hematopoietic regulators, including granulocyte‑macrophage colony‑stimulating factor, thrombopoietin and erythropoietin. In conclusion, the present findings support the potential of MSC‑derived EVs as a treatment for AA by improving hematopoietic function.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: